Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1994 1
2004 1
2007 1
2009 1
2010 1
2011 4
2012 2
2013 1
2014 1
2015 2
2016 3
2019 1
2020 2
2021 2
2022 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Myelodysplastic syndrome with excess blasts-2"
Page 1
Patients With a History of Chemotherapy and Isolated del(20q) With Minimal Myelodysplasia Have an Indolent Course.
Courville EL, Singh C, Yohe S, Linden MA, Naemi K, Berger M, Ustun C, McKenna RW, Dolan M. Courville EL, et al. Am J Clin Pathol. 2016 Apr;145(4):459-66. doi: 10.1093/ajcp/aqw024. Epub 2016 Mar 25. Am J Clin Pathol. 2016. PMID: 27124938
OBJECTIVES: Isolated deletion (20q) is relatively common in myeloid neoplasms and has been rarely reported in cases of therapy-related myelodysplastic syndrome (MDS). Our aim was to characterize cases of isolated del(20q) in bone marrow biopsy specimens from patient …
OBJECTIVES: Isolated deletion (20q) is relatively common in myeloid neoplasms and has been rarely reported in cases of therapy-related my …
Cytogenetic characteristics and prognosis analysis in 231 myelodysplastic syndrome patients from a single institution.
Jung SW, Lee SY, Jekarl DW, Kim M, Lim J, Kim Y, Han K, Kim YJ, Cho SG, Song J. Jung SW, et al. Leuk Res. 2011 Jun;35(6):735-40. doi: 10.1016/j.leukres.2010.11.009. Epub 2010 Dec 13. Leuk Res. 2011. PMID: 21146871
We analyzed the clinical and hematologic data of 231 patients diagnosed with de novo myelodysplastic syndrome (MDS), identified cytogenetic characteristics, and evaluated the significance of prognostic systems. ...In addition, WPSS and age group are applicabl …
We analyzed the clinical and hematologic data of 231 patients diagnosed with de novo myelodysplastic syndrome (MDS), identifie …
Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities.
Ronaghy A, Hu S, Tang Z, Wang W, Tang G, Loghavi S, Li S, Thakral B, Medeiros LJ, Muzzafar T. Ronaghy A, et al. Mod Pathol. 2021 Feb;34(2):300-313. doi: 10.1038/s41379-020-00663-z. Epub 2020 Oct 27. Mod Pathol. 2021. PMID: 33110238 Free article.
Sporadic reports of t(3;12)(q26.2;p13) indicate that this abnormality is associated with myeloid neoplasms, myelodysplasia, and a poor prognosis. To better characterize neoplasms with this abnormality, we assessed 20 patients utilizing clinicopathological data, cytogenetic …
Sporadic reports of t(3;12)(q26.2;p13) indicate that this abnormality is associated with myeloid neoplasms, myelodysplasia, and a poor pr …
De Novo myelodysplastic syndromes in patients 20-50 years old are enriched for adverse risk features.
Epstein-Peterson ZD, Spitzer B, Derkach A, Arango JE, McCarter JGW, Medina-Martínez JS, McGovern E, Farnoud NR, Levine RL, Tallman MS. Epstein-Peterson ZD, et al. Leuk Res. 2022 Jun;117:106857. doi: 10.1016/j.leukres.2022.106857. Epub 2022 May 10. Leuk Res. 2022. PMID: 35598475 Free PMC article.
Data concerning the treatment approach and clinical outcomes in younger patients with myelodysplastic syndromes (MDS) are lacking. Furthermore, published results from genomic profiling in the young adult MDS population are few. ...Clinical information and results fr …
Data concerning the treatment approach and clinical outcomes in younger patients with myelodysplastic syndromes (MDS) are lack …
Epigenetic changes in FOXO3 and CHEK2 genes and their correlation with clinicopathological findings in myelodysplastic syndromes.
Sharifi MJ, Zaker F, Nasiri N, Yaghmaie M. Sharifi MJ, et al. Hematol Oncol Stem Cell Ther. 2020 Dec;13(4):214-219. doi: 10.1016/j.hemonc.2019.11.004. Epub 2020 Mar 18. Hematol Oncol Stem Cell Ther. 2020. PMID: 32217071 Free article.
OBJECTIVES/BACKGROUND: Myelodysplastic syndromes (MDSs) are a heterogeneous disease in terms of clinical course and response to therapy. ...METHODS: A total of 54 newly diagnosed MDS patients referred to Shariati and Firouzgar Hospitals (Tehran, Iran) were in …
OBJECTIVES/BACKGROUND: Myelodysplastic syndromes (MDSs) are a heterogeneous disease in terms of clinical course and res …
Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia.
AlMozain N, Mashi A, Alneami Q, Al-Omran A, Bakshi N, Owaidah T, Khalil S, Khogeer H, Hashmi S, Al-Sweedan S, Morris T, AlNounou R. AlMozain N, et al. Hematol Oncol Stem Cell Ther. 2022 Jun 1;15(2):39-44. doi: 10.1016/j.hemonc.2020.11.001. Hematol Oncol Stem Cell Ther. 2022. PMID: 33227261
BACKGROUND/OBJECTIVE: Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells, characterized by ineffective hematopoiesis, peripheral cytopenias along with hypercellularity of the bone marrow, and marked dysplastic features. ...According to t …
BACKGROUND/OBJECTIVE: Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells, characterized by ineffe …
Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.
Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Ardanaz MT, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa L. Calvo X, et al. Mod Pathol. 2016 Dec;29(12):1541-1551. doi: 10.1038/modpathol.2016.146. Epub 2016 Aug 26. Mod Pathol. 2016. PMID: 27562492 Free article.
We conducted a retrospective study of patients with de novo erythroleukemia and compared their clinico-biological features and outcome with those of de novo myelodysplastic syndromes, focusing on erythroid-predominant myelodysplastic syndromes. ...Our …
We conducted a retrospective study of patients with de novo erythroleukemia and compared their clinico-biological features and outcome with …
Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results.
Wieduwilt MJ, Pawlowska N, Thomas S, Olin R, Logan AC, Damon LE, Martin T, Kang M, Sayre PH, Boyer W, Gaensler KML, Anderson K, Munster PN, Andreadis C. Wieduwilt MJ, et al. Clin Cancer Res. 2019 Aug 15;25(16):4917-4923. doi: 10.1158/1078-0432.CCR-19-0171. Epub 2019 May 31. Clin Cancer Res. 2019. PMID: 31152020 Clinical Trial.
Fifteen patients had de novo AML, six AML with myelodysplasia-related changes, two AML with prior myeloproliferative neoplasm, one therapy-related myeloid neoplasm, and one myelodysplastic syndrome with excess blasts-2. No dose-limiting toxicities occurred in …
Fifteen patients had de novo AML, six AML with myelodysplasia-related changes, two AML with prior myeloproliferative neoplasm, one therapy-r …
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB, Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM, Kmieciak M, Shrader E, Wellons MD, Sankala H, Doyle A, Wright J, Roberts JD, Grant S. Holkova B, et al. Clin Cancer Res. 2013 Apr 1;19(7):1873-83. doi: 10.1158/1078-0432.CCR-12-2926. Epub 2013 Mar 20. Clin Cancer Res. 2013. PMID: 23515411 Free PMC article. Clinical Trial.
PURPOSE: This phase I study was conducted to identify the maximum-tolerated dose (MTD) of alvocidib when combined with vorinostat in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. ...
PURPOSE: This phase I study was conducted to identify the maximum-tolerated dose (MTD) of alvocidib when combined with vorinostat in patient …
Acute Promyelocytic Leukemia Suggesting a Diagnosis of Myelodysplastic Syndrome: a Diagnostic Dilemma.
Shang H, Zhao L, Li R. Shang H, et al. Clin Lab. 2022 Sep 1;68(9). doi: 10.7754/Clin.Lab.2021.211139. Clin Lab. 2022. PMID: 36125158
METHODS: We report here for the first time a rare morphological variant of APL mimicking myelodysplastic syndrome. A 49-year-old man presented with pancytopenia. ...RESULTS: The patient was diagnosed with acute promyelocytic leukemia according to WHO classification. …
METHODS: We report here for the first time a rare morphological variant of APL mimicking myelodysplastic syndrome. A 49-year-o …
25 results